Table 6 Association of the DAS28-ESR and HAQ with ACarPA using all available follow-up dataa.

From: Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies

Measure/Adjustment

Estimate (B)b

SE

p

Time interaction p

DAS28-ESR

noc

0.46

0.10

1.6 × 10–6

0.13

nocrlc

0.42

0.10

1.5 × 10–5

0.19

basicc

0.45

0.10

2.3 × 10–6

0.15

basiccrlc

0.38

0.09

5.3 × 10–5

0.18

basic + CCP & RFc

0.28

0.10

5.2 × 10–3

0.17

basic + CCP & RFcrlc

0.28

0.10

6.4 × 10–3

0.18

HAQ

noc

0.03

0.04

0.47

0.022

basic + CCP & RFc

0.02

0.05

0.61

0.031

  1. aAnalyzed with mixed effects pattern mixture models including all available follow-up data for DAS28-ESR or HAQ, respectively.
  2. bThe estimated (B) overall increase in the activity measure in ACarPA+ relative to ACarPA− patients, its standard error (SE) and p value are presented, as well as, the p values for the ACarPA status interaction with time.
  3. cThe analyses were performed as in Table 2 except when controlled (crl) by the inclusion of the two patterns showing MNAR data.
Back to article page